Survival with Provenge - Real World Data Along with A Peek Into the Future of Treatment

Joel T Nowak from Cancer ABCs discusses with Dr. Rana McKay, Associate Professor of Medicine at the Moores Cancer Center at the University of California in San Diego, her recently published article that analysizes real world data that demonstrates that Provenge (sipuleucel-T), an immune therapy for castrate resistant metastatic prostate cancer (mCRPC), can reduce the risk of death over and above the newer hormone treatments that have been FDA approved . Dr, McKay evaluated a large medicare data base and determined that despite the addition of the many second generation hormone treatments like Zytiga and Xtandi, Provenge continues to lower the risk of death for men with mCRPC. Dr. Mckay also shared a peek into the future of additional immune therapies for prostate cancer as well as sharing information about the newly FDA approved part inhibitors. Cancer ABCs would like to thank its podcast sponsors for their support of this podcast program. Our sponsors include: Myovant/Pfizer Foundation Medicine Bayer Dendreon Support the show

You can listen to Survival with Provenge - Real World Data Along with A Peek Into the Future of Treatment online on Radio and Podcast. Open the player on this page to stream the available audio.

Survival with Provenge - Real World Data Along with A Peek Into the Future of Treatment is an episode from Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer by Joel Nowak Cancer ABCs.

This episode is 25:51 long.

This episode was published on Dec 21, 2020.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer when more episodes are available from the podcast feed.